Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk's Xultophy diabetes combo approved in Europe

Once-daily injection combines the firm's Tresiba and Victoza

Novo Nordisk headquarters 

Novo Nordisk is preparing to launch Xultophy in its first countries in the European Union in the first half of next year after gaining European Commission approval for the diabetes treatment.

Xultophy (formerly known as IDegLira) combines the Danish pharma company's Tresiba (insulin degludec) with its market-leading GLP-1 analogue Victoza (liraglutide) in a once-daily injection.

The new treatment is indicated for adults with type 2 diabetes to help them improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.

Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk, said: “We believe that Xultophy represents a new paradigm with the potential to transform how type 2 diabetes is treated. We look forward to making the product available to people with type 2 diabetes in Europe.”

Xultophy's European approval was based on late-stage studies showing it can avoid common side effects of insulin treatment while still lowering blood sugar levels.

The EC's decision follows the Swiss license Novo received for Xultophy earlier this month and its 2012 Japanese approval.

This success is in stark contrast to the product's fortunes in the US where the FDA has yet to approve the Tresiba part of the combination, delaying Novo's launch not only of Tresiba as a monotherapy and Xultophy, but also its combination treatment Ryzodeg (which adds insulin aspart to Tresiba).

Article by
Dominic Tyer

19th September 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics